continu share gain reduct
messag although rx margin front-end fe comp remain challeng
us market appear near inflect point underpin buy rate
combin signific gener deploy toward
share repurchas modest valuat partial insul tariff freight labor
cost pressur rais pt exhibit inclus
dividend expect total return approach next year acknowledg
likelihood anoth sub-par growth quarter captur expect
result noisi softtax rate drive upsid wba oper result
noisi soft non-recur item permeat laid exhibit
total sale rose healthi led gain us acquir
store respons organ growth howev us wholesal
ebit flat intern retail ebit declin profit margin erod
segment said factor rang busi divestitur account chang
ep beat
us margin pressur could near end wba us segment
character robust top-lin sub-par bottom-lin momentum past three
quarter laid exhibit sale growth run ebit
gener flat profit margin erod basi point dichotomi reflect
acquisit nearli store well rapid growth low-margin specialti
rx busi believ store carri below-averag margin
initi integr potenti disrupt core inclus cycl integr
matur proactiv cost reduct ramp margin stability/modest expans
three-year proactiv cost reduct program latest phase streamlin one
global scope includ consolid dc intern wholesal segment
region cutback retail market like mexico chile smart spend zbb-
like initi across enterpris given like ramp effort believ cost
save could stagger like million year one million year two
million year three even save find way bottom
line ebitda lift would
billion free yield offer option secular ep
growth algorithm would reli heavili rx share gain aforement cost reduct
redeploy signific repurchas share short like
equal exceed billion annual next year compani could drive
ep growth pure re-deploy henc ebit growth would
requir doesnt appear us unreason long comp script
better streamlin effort success time
model beyond
page analyst certif import disclosur
exhibit path price ebitda
compani data guggenheim secur llc estim
page analyst certif import disclosur
share current equival ownership enterpris ebitda ev ebitda epsimpli price earn million except share pricecurr drug store
compani data guggenheim secur llc
page analyst certif import disclosur
pharmaci usa y/i pharmaci intern y/i wholesal y/i elimin y/i cog gross cog gross fifo gross y/i sg y/i expens equiti net incom allianc boot acquisit relat amort cost adjust equiti net incom allianc fifo y/i ebit pharmaci usa fifo y/i ebit pharmaci intern fifo y/i ebit wholesal fifo y/i ebit elimin fifo depreci fifo y/i ebit interest expens incom pre-tax y/i incom tax net incom equiti net y/i net incom equiti method invest y/i interest incom attribut y/i usd drug store
compani data guggenheim secur llc
page analyst certif import disclosur
y/i total number locationsna na y/i changena na pharmaci y/i rx script equival script number scriptsna na number equival front-end y/i fe gross lifo optim gross y/i gross y/i bp acquisit relat amort acquisit relat asset impair store closur optim sg y/i sg y/i bp oper incom ab oper incom ab y/i ebit y/i bp equiti incom fmv warrant gain equiti incom acquisit relat amort oper oper y/i ebit y/i bp usd drug store
exhibit three quarter sub-par us growth could come end
compani data guggenheim secur llc estim
wba current valuat histor level share trade ebitda
ep compar five-year histor averag consensu ntm ebitda consensu ntm ep
believ wba current valuat remain attract room multipl expans investor gain addit clariti
around potenti improv ebit margin market share gain within segment realiz synergi associ
store acquisit price target base target price-to-earnings ep
ebitda previous ep ebitda
primari risk thesi compani inabl reduc oper cost within
segment off-set secular gross margin eros would pressur ebit margin intens retail promot price
environ would limit front-end margin expans weaker-than-anticip front-end demand due current econom
environ would make difficult achiev expens leverag
page analyst certif import disclosur
quarterli annual incom statement august fiscal year end
adust equiti net incom allianc boot
fulli adjust equiti net incom allianc boot
sale
adjust net incom equiti net earn
equiti net incom equiti method invest
invest amerisourcebergen
net incom attribut walgreen
compani data guggenheim secur llc estim
page analyst certif import disclosur
 segment
number locat
total
number script
number equival script
total
gaap equiti incom ab
less fmv warrant gain loss
adjust equiti incom ab
revenu
compani data guggenheim secur llc estim
page analyst certif import disclosur
 segment
number drug store locat
revenu
compani data guggenheim secur llc estim
page analyst certif import disclosur
 segment
number distribut center
gaap equiti incom
chang fair market vale warrant
adjust equiti incom amerisourcebergen
revenu
compani data guggenheim secur llc estim
page analyst certif import disclosur
